It will assist the physician in identifying the patients most likely to benefit from local salvage therapy. It provides information that complements PSA, Gleason score and clinical stage. Prostate cancer is the most common neoplasm found in men over 50 and the second leading cause of male cancer death. The 1997 estimates predict 334,500 new cases and 41,800 deaths. An annual screening should be done starting at age 50, and if there is a family history, age 40.
Definite diagnosis is made by biopsy.
There is a minimum of two sessions. The first session requires no special preparation. About 30 minutes after ProstaScint has been administered the patient is scanned for approximately one hour. This is critical to identify the location of blood vessels. The second session has some preparation.